CN114426541B - 氮杂芳基化合物及其用途 - Google Patents
氮杂芳基化合物及其用途 Download PDFInfo
- Publication number
- CN114426541B CN114426541B CN202111255588.1A CN202111255588A CN114426541B CN 114426541 B CN114426541 B CN 114426541B CN 202111255588 A CN202111255588 A CN 202111255588A CN 114426541 B CN114426541 B CN 114426541B
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- compound
- alkyl group
- pharmaceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 101000866766 Homo sapiens Polycomb protein EED Proteins 0.000 claims abstract description 24
- 102100031338 Polycomb protein EED Human genes 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 4
- 108010085220 Multiprotein Complexes Proteins 0.000 abstract 1
- 102000007474 Multiprotein Complexes Human genes 0.000 abstract 1
- -1 2-oxo-pyrrolidin-3-yl Chemical group 0.000 description 28
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 21
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 19
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 229910052805 deuterium Inorganic materials 0.000 description 13
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 description 12
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000003852 triazoles Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical group C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 3
- PMUHZJKXCBFDEV-UHFFFAOYSA-N 1-(2-fluorophenyl)cyclopropan-1-amine Chemical compound C=1C=CC=C(F)C=1C1(N)CC1 PMUHZJKXCBFDEV-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102000004586 YY1 Transcription Factor Human genes 0.000 description 2
- 108010042669 YY1 Transcription Factor Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical class O1C(CC=C1)* 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DIWHJJUFVGEXGS-UHFFFAOYSA-N 1-(2-fluorophenyl)ethanamine Chemical group CC(N)C1=CC=CC=C1F DIWHJJUFVGEXGS-UHFFFAOYSA-N 0.000 description 1
- VENQOHAPVLVQKV-UHFFFAOYSA-N 1-(2-methoxyphenyl)ethanamine Chemical group COC1=CC=CC=C1C(C)N VENQOHAPVLVQKV-UHFFFAOYSA-N 0.000 description 1
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- DYIRSNMPIZZNBK-UHFFFAOYSA-N N-(furan-2-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12 DYIRSNMPIZZNBK-UHFFFAOYSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 description 1
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000006230 breast fibrosarcoma Diseases 0.000 description 1
- 201000000488 breast squamous cell carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- WYXUZTXCGKPAEH-UHFFFAOYSA-N bromoethane;magnesium Chemical compound [Mg].CCBr WYXUZTXCGKPAEH-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 150000001941 cyclopentenes Chemical class 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
- 150000001942 cyclopropanes Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002523 pancreas lymphoma Diseases 0.000 description 1
- 201000002526 pancreas sarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000013274 squamous cell breast carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明提供了一类氮杂芳基化合物，或其立体异构体、或其药学上可接受的盐。本发明还提供了该类化合物及其组合物在作为制备治疗与EED蛋白和/或PRC2蛋白复合物相关疾病的药物中的用途。
Description
技术领域
本发明涉及一类新的氮杂芳基化合物及其在作为制备治疗与EED蛋白和/或PRC2蛋白复合物相关疾病的药物中的用途。
背景技术
多梳基因家族PcG(Polycomb Group genes)是重要的表观遗传修饰基因，PRC2(Polycomb Repressive Complex 2)作为PcG复合体的重要复合物之一,主要包括EZH2(Enhancer of Zeste Homolog 2)、SUZ12(Suppressor of Zeste 12Homologue)、EED(Embryonic Ectoderm Development)和YYl(Yin Yang 1)。PRC2是通过对染色质中组蛋白3的27位赖氨酸(H3K27)的甲基化修饰来抑制相关基因的表达。其中EZH2具有酶催化活性，能够把底物SAM(S-adenosyl-L-methionine)的甲基转移到H3K27上，从而达到H3K27的一到三甲基化修饰。EZH2的酶催化活性也依赖于PRC2其他组成部分，比如属于WD40重复结构蛋白家族的EED蛋白。PRC2的功能异常与临床上许多肿瘤疾病相关，包括肺癌、乳腺癌、直肠癌、前列腺癌、膀胱癌、胰腺癌、肉瘤以及淋巴癌等等。因此研发抑制PRC2的药物具有重要价值。
抑制PRC2药物的研发目前有EZH2抑制剂以及EED抑制剂两个方向，其中EZH2抑制剂目前已有进入临床，例如EPZ-6438、GSK2816126等。EED抑制剂对EZH2酶功能有变构抑制的作用，可以达到与EZH2相同或类似的生物功能。并且EED抑制剂还可能会克服了EZH2抑制剂的耐药性问题，与EZH2抑制剂联用也可能达到更好的协同作用。
发明内容
本发明提供了一种式I所示的化合物、或其立体异构体、或其药学上可接受的盐：
其中，
A环选自5～6元杂环烷基、苯环、5～6元芳杂环或-(苯环)-(5～6元杂环烷基)；其中杂环烷基、苯环、芳杂环可进一步被一个、两个或三个RA1取代；
每个RA1分别独立选自氢、氘、卤素、氰基、硝基、C1～6烷基、卤素取代的C1～6烷基、-ORA2、-NRA2RA3、-C(O)RA2、-S(O)RA2、-S(O)2RA2、3～6元环烷基；
RA2、RA3分别独立选自氢、氘、C1～6烷基、3～6元环烷基；
R1选自氢、氘、C1～6烷基、氘取代的C1～6烷基；
R2、R3分别独立选自氢、氘、卤素、C1～6烷基、氘取代的C1～6烷基、卤素取代的C1～6烷基；且R2、R3不同时为氢；
或者，R2、R3相连形成3～6元环烷基、氘取代的3～6元环烷基；
R4、R5分别独立选自氢、C1～6烷基；
或者，R4、R5相连形成5～6元环烷基、氘取代的5～6元环烷基、5～6元杂环烷基、氘取代的5～6元杂环烷基、5～6元芳杂环、氘取代的5～6元芳杂环；
或者，R2、R4相连形成5～6元环烷基、氘取代的5～6元环烷基、5～6元杂环烷基、氘取代的5～6元杂环烷基；
R6选自氢、卤素、氰基、硝基、C1～6烷基、卤素取代的C1～6烷基、-OR62、-NR62R63、3～6元环烷基；
R62、R63分别独立选自氢、C1～6烷基。
进一步地，
A环选自吡啶、哌嗪、苯环或-(苯环)-(哌嗪)；其中吡啶、哌嗪、苯环可进一步被一个、两个或三个RA1取代；
每个RA1分别独立选自氢、氘、卤素、氰基、硝基、C1～4烷基、卤素取代的C1～4烷基、-ORA2、-NRA2RA3、-C(O)RA2、-S(O)RA2、-S(O)2RA2、环丙基；
RA2、RA3分别独立选自氢、氘、C1～4烷基、环丙基；
R1选自氢、氘、C1～4烷基、氘取代的C1～4烷基；
R2、R3分别独立选自氢、氘、卤素、C1～4烷基、氘取代的C1～4烷基、卤素取代的C1～4烷基；且R2、R3不同时为氢；
或者，R2、R3相连形成环丙烷、氘取代的环丙烷；
R4、R5分别独立选自氢、C1～4烷基；
或者，R4、R5相连形成二氢呋喃、呋喃、氘取代的二氢呋喃、氘取代的呋喃；
或者，R2、R4相连形成环戊烯、氘取代的环戊烯；
R6选自氢、卤素、氰基、硝基、C1～4烷基、卤素取代的C1～4烷基、-OR62、-NR62R63、环丙烷；
R62、R63分别独立选自氢、C1～4烷基。
更进一步地，
A环选自
更进一步地，式I所示的化合物如下所示：
更进一步地，式I所示的化合物如下所示：
在本发明的一些具体实施方案中，所述化合物具体为：
本发明还提供了前述的化合物、或其立体异构体、或其药学上可接受的盐在制备药物中的用途。
本发明还提供了前述的化合物、或其立体异构体、或其药学上可接受的盐在制备治疗与EED蛋白和/或PRC2蛋白复合物相关疾病的药物中的用途。
进一步地，所述与EED和/或PRC2蛋白复合物活性相关的疾病为肿瘤、癌症、癌前期综合征相关的疾病中的一种或几种。
本发明还提供了一种药物组合物，以前述的化合物、或其立体异构体、或其药学上可接受的盐，加上药学上可接受的辅料制备而成的制剂。
“癌症”或“肿瘤”是指以不受控制的细胞异常增殖为特征的多种疾病中的任何一种，受影响的细胞在局部或通过血流和淋巴系统扩散到其他部位的能力的身体(即转移)以及许多特征结构和/或分子特征中的任何一个。“癌细胞”是指经历多步骤肿瘤进展的早期，中期或晚期阶段的细胞。癌症包括肉瘤、乳腺癌、肺癌、脑癌、骨癌、肝癌、肾癌、结肠癌和前列腺癌。在一些实施方案中，式I的化合物用于治疗选自结肠癌、脑癌、乳腺癌、纤维肉瘤和鳞状细胞癌的癌症。在一些实施方案中，癌症选自黑素瘤、乳腺癌、结肠癌、肺癌和卵巢癌。在一些实施方案中，所治疗的癌症是转移性癌症。
本发明中提供的化合物和衍生物可以根据IUPAC(国际纯粹与应用化学联合会)或CAS(化学文摘服务社，Columbus，OH)命名系统命名。
关于本发明的使用术语的定义：除非另有说明，本文中基团或者术语提供的初始定义适用于整篇说明书的该基团或者术语；对于本文没有具体定义的术语，应该根据公开内容和上下文，给出本领域技术人员能够给予它们的含义。
“取代”是指分子中的氢原子被其它不同的原子或基团所替换。
“可进一步被取代”是指“取代”可以但不必须发生，该说明包括发生或不发生的情形。
碳氢基团中碳原子含量的最小值和最大值通过前缀表示，例如，前缀Ca～b烷基表明任何含“a”至“b”个碳原子的烷基。因此，例如，C1～4烷基是指包含1～4个碳原子的烷基。
“烷基”是指具有指定数目的成员原子的饱和烃链。烷基基团可以是直链或支链的。代表性的支链烷基基团具有一个、两个或三个支链。烷基基团可任选地被一个或多个如本文所定义的取代基取代。烷基包括甲基、乙基、丙基(正丙基和异丙基)、丁基(正丁基、异丁基和叔丁基)、戊基(正戊基、异戊基和新戊基)和己基。烷基基团也可以是其他基团的一部分，所述其他基团为例如C1～C6烷氧基。
本发明中Ca～b烷氧基、Ca～b烷酯基、Ca～b烷氨基、Ca～b酰基分别是指含有“a”至“b”个碳原子的烷基与对应的氧原子、酯基、氨基、酰基相连得到的基团。
本发明中所述的“环烷基”、“环烷烃”是指具有多个碳原子且没有环杂原子且具有单个环或多个环(包括稠合、桥连和螺环体系)的饱和或部分饱和的环状基团。对于具有不含环杂原子的芳族和非芳族环的多环体系，当连接点位于非芳族碳原子时，适用术语“环烷基”(例如5,6,7,8,-四氢化萘-5-基)。术语“环烷基”包括环烯基基团，诸如环己烯基。环烷基基团的实例包括例如，金刚烷基、环丙基、环丁基、环己基、环戊基、环辛基、环戊烯基和环己烯基。包括多双环烷基环体系的环烷基基团的实例是双环己基、双环戊基、双环辛基等。下面例举并命名两种此类双环烷基多环结构：
双环己基和/>
双环己基。
本发明中所述的“杂环”、“杂环烷基”、“杂环烷烃”是指包含至少一个杂原子的饱和环或非芳香性的不饱和环；其中杂原子指氮原子、氧原子、硫原子等。通常表示多个环原子的一价饱和或部分不饱和单环或二环环系统、优选3至9个环原子的一价饱和或部分不饱和单环或二环环系统，其包含1、2或3个选自N、O和S的环杂原子，其余的环原子是碳。二环表示由共有两个环原子的两个环组成的，即将两个环分开的桥是单键或是一个或两个环原子的链。单环饱和杂环烷基的实例是氧杂环丁基、氮杂环丁基、吡咯烷基、2-氧代-吡咯烷-3-基、四氢呋喃基、四氢-噻吩基、吡唑烷基、咪唑烷基、噻唑烷基、哌啶基、四氢吡喃基、四氢噻喃基、哌嗪基、吗啉基、
硫代吗啉基、1，1-二氧代-硫代吗啉-4-基、氮杂环庚基、二氮杂环庚基、高哌嗪基或氧杂氮杂环庚基。二环饱和杂环烷基的实例是8-氮杂-二环[3.2.1]辛基、奎宁环基、8-氧杂-3-氮杂-二环[3.2.1]辛基、9-氮杂-二环[3.3.1]壬基、
部分不饱和杂环烷基的实例是二氢呋喃基、咪唑啉基、四氢-吡啶基或二氢吡喃基。
本发明中所述的“芳环”是指具有多个碳原子的芳烃基团。芳基通常是具有6-20个碳原子的单环、二环或三环芳基。此外，本文所用的术语“芳基”是指可以是单个芳环或稠合在一起的多个芳环的芳族取代基。非限制性实例包括苯基、萘基或四氢萘基。
本发明中所述的“芳杂环”是指包含至少一个杂原子的芳香性不饱和环；其中杂原子指氮原子、氧原子、硫原子等。通常包含多个环原子的、其中一个或多个环原子选自O、N、S的杂原子的芳族单环或双环烃。优选地有一到三个杂原子。杂环芳基例如代表：吡啶基、吲哚基、喹噁啉基、喹啉基、异喹啉基、苯并噻吩基、苯并呋喃基、苯并噻吩基、苯并吡喃基、苯并噻吡喃基、呋喃基、吡咯基、噻唑基、噁唑基、异噁唑基、三唑基、四唑基、吡唑基、咪唑基、噻吩基、噁二唑基、苯并咪唑基、苯并噻唑基、苯并噁唑基。
本发明中所述的“卤素”是指氟、氯、溴或碘。
本发明中所述的“卤素取代的烷基”、“氘取代的烷基”、“氘取代的环烷基”是指烷基中的一个或多个氢原子被卤素或氘取代；例如三氟甲基。
本发明中所述的“-OR”、“-NRR”等是指R基团与氧原子或氮原子以单键相连。
本发明中所述的“-C(O)R”、“-S(O)2R”等中的氧原子是与碳原子或硫原子以双键相连。
术语“药学上可接受的”是指某载体、运载物、稀释剂、辅料，和/或所形成的盐通常在化学上或物理上与构成某药物剂型的其它成分相兼容，并在生理上与受体相兼容。
术语“盐”和“可药用的盐”是指上述化合物或其立体异构体，与无机和/或有机酸和碱形成的酸式和/或碱式盐，也包括两性离子盐(内盐)，还包括季铵盐，例如烷基铵盐。这些盐可以是在化合物的最后分离和纯化中直接得到。也可以是通过将上述化合物，或其立体异构体，与一定数量的酸或碱适当(例如等当量)进行混合而得到。这些盐可能在溶液中形成沉淀而以过滤方法收集，或在溶剂蒸发后回收而得到，或在水介质中反应后冷冻干燥制得。本发明中所述盐可以是化合物的盐酸盐、硫酸盐、枸橼酸盐、苯磺酸盐、氢溴酸盐、氢氟酸盐、磷酸盐、乙酸盐、丙酸盐、丁二酸盐、草酸盐、苹果酸盐、琥珀酸盐、富马酸盐、马来酸盐、酒石酸盐或三氟乙酸盐。
在某些实施方式中，本发明的一种或多种化合物可以彼此联合使用。也可选择将本发明的化合物与任何其它的活性试剂结合使用，用于制备调控细胞功能或治疗疾病的药物或药物组合物。如果使用的是一组化合物，则可将这些化合物同时、分别或有序地对受试对象进行给药。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
化合物的结构是通过核磁共振(NMR)或(和)质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的的单位给出。NMR的测定是用(Bruker AvanceIII 400和Bruker Avance 300)核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d6)，氘代氯仿(CDCl3),氘代甲醇(CD3OD)，内标为四甲基硅烷(TMS)。
LC-MS的测定使用岛津液质联用仪(Shimadzu LC-MS 2020(ESI))。HPLC的测定使用岛津高压液相色谱仪(Shimadzu LC-20A)。MPLC(中压制备色谱)使用Gilson GX-281反相制备色谱仪。薄层层析硅胶板用烟台黄海HSGF254或青岛GF254硅胶板，薄层层析分离纯化产品采用的规格是0.4mm～0.5mm。柱层析一般使用烟台黄海硅胶200～300目硅胶为载体。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买于安耐吉化学、成都科龙化工、韶远化学科技、百灵威科技等公司。
实施例中无特殊说明，反应在氮气氛围下进行。实施例中无特殊说明，溶液是指水溶液。实施例中无特殊说明，反应的温度为室温。实施例中无特殊说明，M是摩尔每升。室温通常为20℃～30℃。过夜为12±1h。
中间体M1、8-溴-5-甲基磺酰-[1,2,4]三唑[4,3-c]嘧啶的合成
步骤1、化合物M1-2的合成
在干燥的250ml单口瓶中加入底物5-溴-4-氯-2-甲基磺酰-嘧啶(1g，4.38mmol)，加入乙醇(20ml)溶解，搅拌下缓慢滴加N2H4 H2O(440mg,9.21mmol)搅拌反应4小时，LC-MS监测。反应结束后用水和乙酸乙酯萃取，有机相用无水硫酸钠干燥后减压浓缩，残余物用柱层析纯化得到产物M1-1(5-溴-2-甲基磺酰-嘧啶-4-基)肼(1.03g,99.9％)LC-MC：m/z 236.1[M+H]+
步骤2、化合物M1的合成
在干燥的250ml单口瓶中加入底物(5-溴-2-甲基磺酰-嘧啶-4-基)肼(750mg，3.19mmol)，加入CH(OMe)3(10ml)溶解，升温至100℃，搅拌反应2.5小时，LC-MS监测。反应结束后用水和乙酸乙酯萃取，有机相用无水硫酸钠干燥后减压浓缩，残余物用柱层析纯化得到产物M1 8-溴-5-甲基磺酰-[1,2,4]三唑[4,3-c]嘧啶(700g,89.5％)LC-MC：m/z 246.1[M+H]+
实施例1、N-(1-(2-氟苯基)环丙基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺的合成
步骤1、化合物1-2的合成
在干燥的250ml单口瓶中加入底物2-氟苯腈(1.21g，9.99mmol)，加入Et2O(40ml)溶解，加入溴(乙基)镁(2.93g，21.98mmol)，Ti(OiPr)4(3.12g，10.99mmol)和BF3OEt2(2.84g，19.98mmol)室温搅拌反应4小时，LC-MS监测。反应结束后用水和乙酸乙酯萃取，有机相用无水硫酸钠干燥后减压浓缩，残余物用柱层析纯化得到产物1-(2-氟苯基)氨基环丙烷(260mg,17.2％)LC-MC：m/z 152.2[M+H]+
步骤2、化合物1-4的合成
在干燥的50ml单口瓶中加入底物8-溴-5-甲基磺酰-[1,2,4]三唑[4,3-c]嘧啶(40mg，0.16mmol)，加入THF(6ml)溶解，加入1-(2-氟苯基)氨基环丙烷(65mg，0.25mmol)，MCPBA(54.8mg，0.32mmol)和TEA(50mg，0.49mmol)室温搅拌反应4小时，LC-MS监测。反应结束后用水和乙酸乙酯萃取，有机相用无水硫酸钠干燥后减压浓缩，残余物用柱层析纯化得到产物8-溴-N-[1-(2-氟苯基)环丙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺(26mg,45.7％)LC-MC：m/z348[M+H]+
步骤3、化合物1的合成
在干燥的50ml单口瓶中加入底物8-溴-N-[1-(2-氟苯基)环丙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺(12.8mg，0.036mmol)，加入1,4二氧六环(3ml)和水(1ml)溶解，加入2-甲基-3-(4,4,5,5-四甲基-1,3,2-二恶硼硼烷-2-基)吡啶(10.4mg，0.047mmol)，Pd(dppf)Cl2(2mg，0.036mmol)和碳酸钠(13mg，0.036mmol)，升温至110℃，在氮气保护下搅拌反应4小时，LC-MS监测。反应结束后用水和乙酸乙酯萃取，有机相用无水硫酸钠干燥后减压浓缩，残余物用柱层析纯化得到产物N-[1-(2-氟苯基)环丙基]-8-(2-甲基-3-吡啶基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺(9.16mg,69.2％)LC-MC：m/z 361[M+H]+
1H NMR(400MHz,Methanol-d4)δ9.42(s,1H),8.75(dd,J＝5.9,1.6Hz,1H),8.54(dd,J＝8.0,1.6Hz,1H),7.96(dd,J＝8.0,5.8Hz,1H),7.83(s,1H),7.79(td,J＝7.7,1.8Hz,1H),7.27(tdd,J＝7.5,5.1,1.8Hz,1H),7.14–7.02(m,2H),2.67(s,3H),1.44(d,J＝2.2Hz,4H),1.31–1.28(m,2H).
实施例2、8-(2-甲基吡啶-3-基)-N-(1-苯乙基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺的合成
步骤1、化合物2-2的合成
按照实施例1中步骤2的合成方法，将步骤2中的1-(2-氟苯基)氨基环丙烷替换为1-苯乙胺，合成方法相同，得到化合物8-溴-N-(1-苯乙基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺LC-MC：m/z 319[M+H]+
步骤2、化合物2的合成
按照实施例1中步骤3的合成方法，将步骤3中的8-溴-N-[1-(2-氟苯基)环丙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺替换为8-溴-N-(1-苯乙基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺，合成方法相同，得到化合物8-(2-甲基吡啶-3-基)-N-(1-苯乙基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺LC-MC：m/z 331[M+H]+
1H NMR(400MHz,DMSO-d6)δ8.84(d,J＝8.4Hz,1H),8.57(s,1H),8.49(dd,J＝4.7,1.7Hz,1H),7.88(s,1H),7.71(d,J＝7.3,1.5Hz,1H),7.52(d,J＝7.6Hz,2H),7.40–7.28(m,3H),7.28–7.19(m,1H),5.54–5.36(m,1H),2.38(s,3H),1.64(d,J＝7.0Hz,3H).
实施例3、N-(1-(2-氟苯基)乙基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺的合成
步骤1、化合物3-2的合成
按照实施例1中步骤2的合成方法，将步骤2中的1-(2-氟苯基)氨基环丙烷替换为1-(2-氟苯基)乙胺，合成方法相同，得到化合物8-溴-N-[1-(2-氟苯基)乙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺LC-MC：m/z 337[M+H]+
步骤2、化合物3的合成
按照实施例1中步骤3的合成方法，将步骤3中的8-溴-N-[1-(2-氟苯基)环丙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺替换为8-溴-N-[1-(2-氟苯基)乙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺，合成方法相同，得到化合物N-(1-(2-氟苯基)乙基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺LC-MC：m/z 349[M+H]+
1H NMR(400MHz,Methanol-d4)δ8.47(dd,J＝5.0,1.7Hz,1H),8.40(s,1H),7.85(s,1H),7.77(dd,J＝7.7,1.7Hz,1H),7.52(td,J＝7.7,1.8Hz,1H),7.36(dd,J＝7.7,4.9Hz,1H),7.32–7.24(m,1H),7.17–7.06(m,2H),5.76(d,J＝7.0Hz,1H),2.42(s,3H),1.71(d,J＝7.0Hz,3H).实施例4和5、(R)-N-(1-(2-甲氧基苯基)乙基)-8-(2-甲基嘧啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺和(S)-N-(1-(2-甲氧基苯基)乙基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺的合成
步骤1、化合物4-2的合成
按照实施例1中步骤2的合成方法，将步骤2中的1-(2-氟苯基)氨基环丙烷替换为1-(2-甲氧基苯基)乙胺，合成方法相同，得到化合物8-溴-N-[1-(2-甲氧基苯基)乙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺LC-MC：m/z 349[M+H]+
步骤2、化合物4和5的合成
按照实施例1中步骤3的合成方法，将步骤3中的8-溴-N-[1-(2-氟苯基)环丙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺替换为8-溴-N-[1-(2-甲氧基苯基)乙基]-[1,2,4]三唑[4,3-c]嘧啶-5-胺，合成方法相同，得到化合物(R)-N-(1-(2-甲氧基苯基)乙基)-8-(2-甲基嘧啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺和(S)-N-(1-(2-甲氧基苯基)乙基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑[4,3-c]嘧啶-5-胺LC-MC：m/z 361[M+H]+
化合物4：1H NMR(400MHz,Methanol-d4)δ9.58(s,1H),8.75(dd,J＝5.9,1.6Hz,1H),8.56(dd,J＝8.0,1.5Hz,1H),7.97(dd,J＝7.9,5.8Hz,1H),7.77(s,1H),7.40(dd,J＝7.6,1.7Hz,1H),7.25(td,J＝7.9,1.7Hz,1H),7.00(dd,J＝8.2,1.0Hz,1H),6.92(td,J＝7.5,1.1Hz,1H),5.78(q,J＝6.9Hz,1H),3.89(s,3H),2.70(s,3H),1.66(d,J＝7.0Hz,3H).
化合物5：1H NMR(400MHz,Methanol-d4)δ8.77(s,1H),8.55(d,J＝7.5Hz,1H),8.45(s,1H),8.03(s,1H),7.97(s,1H),7.37(d,J＝7.6Hz,1H),7.26(t,J＝7.9Hz,1H),7.03(d,J＝8.3Hz,1H),6.92(t,J＝7.4Hz,1H),5.77(t,J＝7.0Hz,1H),3.94(s,3H),2.69(s,3H),1.66(d,J＝6.9Hz,3H).
以下用试验例的方式说明本发明的有益效果：
试验例、生物活性实验
多梳抑制复合物PRC2广泛参与肿瘤的发生与恶化，其抑制剂发现是目前表观遗传抗肿瘤药物研究中的热点。EED和EZH2是PRC2的核心成分之一，EED具有结合(H3K27me3)小肽作用，结合H3K27me3后，将PRC2定位在染色质上，并充当支架功能，提供一个EZH2可催化的结构，从而刺激PRC2的甲基转移酶活性，使得H3K27ME3标记在染色质上传播。由于PRC2的催化活性依赖于EZH2与EED的蛋白-蛋白相互作用，靶向EED的小分子抑制剂可能抑制PRC2的致癌活性。因此，寻找抑制EED的化合物为抑制PRC2活性提供了新方法。本发明公开了化合物可以作为EED靶点抑制剂，并对EED和/或PRC2作用机理相关的疾病有治疗作用。
本发明公开化合物的生物学功能在生化水平的测试中得到了证明。在生化测试中，本发明公开的化合物能够与和EED蛋白结合的H3K27Me3多肽有强的竞争结合作用。
试验例1：通过TR-FRET方法评价化合物在阻断EED与H3K27me3结合的效果
首先配置不同浓度梯度的化合物溶液。取DMSO溶解到浓度为2～50mM测试化合物和40mM参考化合物EED226(Cayman,22031)和A-395(Sigma,SML 1923-5MG)将化合物用100％DMSO进行2倍或3倍稀释，配制成200×DMSO溶液，共9个剂量点。取2μL 200×稀释好的化合物到98μL反应缓冲液(25mM Hepes,0.01％BSA,0.5mM DTT,1mM EDTA,pH 8.0)中混匀。取5μL不同浓度梯度的化合物至384检测板(Corning,3574)中，每个浓度梯度设置2个平行重复。
其次进行结合阻断反应。用上述反应缓冲液稀释Flag-EED(BPS,50280)蛋白至40nM，以及生物素标记的多肽片段H3K27(1-50)me3-biotin peptide(Cisbio定制)至400nM。底物序列为ARTKQTARKSTGGKAPRKQLATKAARK(me3)SAPATGGVKKPHRYRPGTVALRE-K(Biotin)。分别转移5μL浓度为400nM多肽片段以及5μL的40nM蛋白至含有化合物的检测孔内，薄膜封住检测板，25℃孵育30min。
最后使用TR-FRET方法检测。分别准备LANCE Eu-W1024 anti-FLAG(供体)(PerkinElmer,AD0273)和Streptavidin-XL665(受体)(PerkinElmer,AL108C)溶液至上述反应缓冲液中，再向各检测孔中加入5μL上述受体和供体，终浓度依次为2nM和50nM。锡箔遮封住检测板，将检测板在25℃，避光孵育60min。使用Tecan Spark 20M读数(用320nm波长为激发光，在665nm和620nm波长值为发射光读荧光信号值)。计算荧光信号比值：665/620*1000为最终的酶活性信号值，根据阳性对照(最大信号对照)和阴性对照(最小信号对照)获得的读数TR-FRET信号进行标准化，以给出不同浓度化合物的抑制率。再通过GraphPadPrism 6以log(inhibitor)vs.response–Variable slope模式拟合计算得出化合物对酶活性抑制的IC50。拟合方程为：Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))，其中Y代表已知的百分剩余酶活性，X代表Log后的已知化合物的浓度。
按照上述方法对实施例制备的化合物进行EED抑制活性检测，试验结果见表1，其中测定各化合物的IC50按照说明分类：
“+”表示IC50测定值小于等于100μM大于1μM；
“++”表示IC50测定值小于等于1μM；
表1、本发明化合物对EED的抑制活性
| 实施例化合物 | EED IC50 |
| 1 | ++ |
| 2 | ++ |
| 3 | ++ |
| 4 | ++ |
| 5 | ++ |
Claims (7)
1.式I所示的化合物、或其药学上可接受的盐：
其中，
A环选自
每个RA1分别独立选自C1～6烷基；
R1选自氢；
R2、R3分别独立选自氢、C1～6烷基；且R2、R3不同时为氢；
或者，R2、R3相连形成3～6元环烷基；
R4、R5分别独立选自氢、C1～6烷基；
R6选自氢、卤素、氰基、硝基、C1～6烷基、卤素取代的C1～6烷基、-OR62；
R62选自C1～6烷基。
2.根据权利要求1所述的化合物、或其药学上可接受的盐，其特征在于：
每个RA1分别独立选自C1～4烷基；
R1选自氢；
R2、R3分别独立选自氢、C1～4烷基；且R2、R3不同时为氢；
或者，R2、R3相连形成环丙烷；
R4、R5分别独立选自氢、C1～4烷基；
R6选自氢、卤素、-OR62；
R62分别独立选自C1～4烷基。
3.根据权利要求1～2任一项所述的化合物、或其药学上可接受的盐，其特征在于：所述化合物具体为：
4.权利要求1～3任一项所述的化合物、或其药学上可接受的盐在制备药物中的用途。
5.权利要求1～3任一项所述的化合物、或其药学上可接受的盐在制备治疗与EED蛋白和/或PRC2蛋白复合物相关疾病的药物中的用途。
6.根据权利要求5所述的用途，其特征在于：所述与EED和/或PRC2蛋白复合物活性相关的疾病为肿瘤、癌症、癌前期综合征相关的疾病中的一种或几种。
7.一种药物组合物，其特征在于：以权利要求1～3任一项所述的化合物、或其药学上可接受的盐，加上药学上可接受的辅料制备而成的制剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011171518 | 2020-10-29 | ||
| CN2020111715183 | 2020-10-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114426541A CN114426541A (zh) | 2022-05-03 |
| CN114426541B true CN114426541B (zh) | 2023-06-30 |
Family
ID=81310832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111255588.1A Active CN114426541B (zh) | 2020-10-29 | 2021-10-29 | 氮杂芳基化合物及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114426541B (zh) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL263429B (en) * | 2016-06-20 | 2022-08-01 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
| CN107186370A (zh) * | 2017-07-28 | 2017-09-22 | 上海嘉强自动化技术有限公司 | 一种新型激光加工头碰板检测装置 |
| CN110156787B (zh) * | 2018-02-13 | 2021-11-02 | 中国科学院上海药物研究所 | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 |
| CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
-
2021
- 2021-10-29 CN CN202111255588.1A patent/CN114426541B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114426541A (zh) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202128691A (zh) | Ｋｒａｓ 突變蛋白抑制劑 | |
| AU2018208231B2 (en) | Imidazopyrazine compound, preparation method therefor and use thereof | |
| KR102359993B1 (ko) | 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도 | |
| WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
| KR20190140966A (ko) | 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물 | |
| CN112409376A (zh) | 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用 | |
| US10501466B2 (en) | WDR5 inhibitors and modulators | |
| US20220041577A1 (en) | Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor | |
| WO2021041976A1 (en) | Perk inhibiting indolinyl compounds | |
| FR2941948A1 (fr) | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src | |
| US9724331B2 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
| CN108137589A (zh) | 作为布罗莫区结构域抑制剂的咔啉衍生物 | |
| KR20220051226A (ko) | 아자헤테로아릴 화합물 및 이의 용도 | |
| CN113166148B (zh) | 作为cdk-hdac双通路抑制剂的杂环化合物 | |
| RU2691401C2 (ru) | Подготовка и использование ингибитора киназы | |
| CN117510503A (zh) | 一种酪氨酸苏氨酸激酶pkmyt1抑制剂 | |
| WO2023125928A1 (zh) | Menin抑制剂及其用途 | |
| CN114426541B (zh) | 氮杂芳基化合物及其用途 | |
| CN110357905B (zh) | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 | |
| CN116162099A (zh) | 杂环类衍生物及其制备方法和用途 | |
| KR20230133396A (ko) | Rip2 키나아제 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도 | |
| CN116655655A (zh) | 四并环化合物及其药物组合物和应用 | |
| US11021479B2 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| CN112209933B (zh) | 含有4-氮杂螺庚烷的btk抑制剂 | |
| KR102218861B1 (ko) | 단백질 키나아제 저해제인 신규한 페녹시 아로마틱 아마이드 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |